QIAGEN Extends Distribution Agreement with Abbott for QIAGEN’s RealArt™ Molecular Diagnostic Tests
Venlo, The Netherlands - June 22, 2005 - QIAGEN N.V. (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids and proteins today announced that Abbott (NYSE: ABT) and QIAGEN have extended their existing distribution agreement. Under the terms of the agreement, Abbott received distribution rights to a number of real-time PCR diagnostic tests for use on Applied Biosystems detection instruments. The PCR assays were developed by artus GmbH, a company QIAGEN recently acquired.
Under the extended agreement Abbott has non-exclusive distribution rights to certain QIAGEN products, including infectious disease tests for hepatitis B virus (HBV), Epstein-Barr virus (EBV), Varicella-Zoster virus (VZV), Parvo B19 virus, cytomegalovirus (CMV), herpes simplex virus (HSV) and enterovirus. These products complement a menu of tests developed and manufactured by Abbott and Celera Diagnostics.
"Real-time PCR is the major driving technology in molecular diagnostics. Following our acquisition of artus GmbH, QIAGEN is now extremely well positioned as a manufacturer and supplier of high quality products in this field," said Noel Doheny, QIAGEN's Vice President Solutions for Molecular Diagnostics. "With artus' RealArtTM assay technology, QIAGEN is now able to provide a broad range of optimized combinations of preanalytical sample preparation and licensed real-time PCR assay kits for pathogen analysis applying PCR in the field of infectious disease, cancer, genetic monitoring, therapeutic drug monitoring and tissue typing to its partners in molecular diagnostics. The extended collaboration with Abbott will provide laboratories worldwide with additional real-time PCR kits for infectious disease testing."
QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the United States, Japan, the United Kingdom, Switzerland, France, Italy, Australia, Norway, Austria, Canada, Sweden, and the Netherlands believes it is the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids and proteins. QIAGEN has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid and protein separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products and related services. QIAGEN's products are sold in more than 42 countries throughout the world to academic research markets and to leading pharmaceutical and biotechnology companies. In addition, QIAGEN is positioning its products for sale into developing commercial markets, including applied testing markets, clinical research, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. QIAGEN employs more than 1,300 people worldwide. Further information on QIAGEN can be found at http://www.qiagen.com/.
Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the applied testing markets and proteomics markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products ( including fluctuations for certain events including funding, budgets, and others ), difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, market acceptance of QIAGEN's new products and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).
IR QIAGEN N.V.
Phone: +49 2103 29 11710
Fax: +49 2103 29 21710